These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33649485)

  • 61. The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study.
    Jil M; Rajnikant M; Richard D; Iskandar I
    Diab Vasc Dis Res; 2017 Jul; 14(4):295-303. PubMed ID: 28330386
    [TBL] [Abstract][Full Text] [Related]  

  • 62. DiaSurg 2 trial--surgical vs. medical treatment of insulin-dependent type 2 diabetes mellitus in patients with a body mass index between 26 and 35 kg/m2: study protocol of a randomized controlled multicenter trial--DRKS00004550.
    Kenngott HG; Clemens G; Gondan M; Senft J; Diener MK; Rudofsky G; Nawroth PP; Büchler MW; Fischer L; Müller-Stich BP
    Trials; 2013 Jun; 14():183. PubMed ID: 23782896
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The effects of AER and eGFR on outcomes of CVD in patients with T2DM in an urban community over 8 years of multifactorial treatment: the Beijing Communities Diabetes Study 18.
    Zhang XL; Yuan MX; Wan G; Yang GR; Li DM; Fu HJ; Zhu LX; Xie RR; Zhang JD; Lv YJ; Li YL; Du XP; Wang ZM; Cui XL; Liu DY; Gao Y; Cheng SY; Wang Q; Ji Y; Li GW; Yuan SY
    Ther Clin Risk Manag; 2018; 14():1537-1545. PubMed ID: 30214217
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Association between Metabolic Syndrome and Morbid Events in Type 2 Diabetes after a 7-Year Community Management: Beijing Community Diabetes Study 17.
    Yang GR; Yuan MX; Fu HJ; Wan G; Li D; Dye TD; Zhu LX; Xie RR; Lv YJ; Zhang JD; Du XP; Li YL; Ji Y; Li Y; Cui XL; Wang ZM; Cheng SY; Liu DY; Wang Q; Zhou L; Gao Y; Yuan SY
    J Diabetes Res; 2019; 2019():5237371. PubMed ID: 31281851
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Acarbose reduces Pseudomonas aeruginosa respiratory tract infection in type 2 diabetic mice.
    Liu L; Fan H; Li L; Fan Y
    Respir Res; 2023 Dec; 24(1):312. PubMed ID: 38098038
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comorbidity of Type 2 Diabetes Mellitus and Depression: Clinical Evidence and Rationale for the Exacerbation of Cardiovascular Disease.
    Zhu M; Li Y; Luo B; Cui J; Liu Y; Liu Y
    Front Cardiovasc Med; 2022; 9():861110. PubMed ID: 35360021
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease: JACC Scientific Statement.
    Forman DE; Kuchel GA; Newman JC; Kirkland JL; Volpi E; Taffet GE; Barzilai N; Pandey A; Kitzman DW; Libby P; Ferrucci L
    J Am Coll Cardiol; 2023 Aug; 82(7):631-647. PubMed ID: 37389519
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Molecular inhibition of RAS signalling to target ageing and age-related health.
    Laskovs M; Partridge L; Slack C
    Dis Model Mech; 2022 Oct; 15(10):. PubMed ID: 36111627
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Acarbose is again on the stage.
    Altay M
    World J Diabetes; 2022 Jan; 13(1):1-4. PubMed ID: 35070055
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24).
    Zhang XL; Yuan SY; Wan G; Yuan MX; Yang GR; Fu HJ; Zhu LX; Zhang JD; Li YL; Gao DY; Cui XL; Wang ZM; Xie RR; Chen YJ
    Sci Rep; 2021 Mar; 11(1):4839. PubMed ID: 33649485
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Improved Framingham Risk Scores of Patients with Type 2 Diabetes Mellitus in the Beijing Community: A 10-Year Prospective Study of the Effects of Multifactorial Interventions on Cardiovascular Risk Factors (The Beijing Communities Diabetes Study 22).
    Zhang XL; Wan G; Yuan MX; Yang GR; Fu HJ; Zhu LX; Xie RR; Lv YJ; Zhang JD; Li YL; Dai QF; Ji Y; Holman RR; Yuan SY;
    Diabetes Ther; 2020 Apr; 11(4):885-903. PubMed ID: 32086768
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The effects of cardiovascular risk factor combined anti-platelet therapy and the risk of cerebrovascular events in patients with T2DM in an urban community over 96-months follow-up: The Beijing communities diabetes study 19.
    Zhang XL; Fu HJ; Yang GR; Wan G; Li D; Zhu LX; Xie RR; Lv YJ; Zhang JD; Li YL; Dai QF; Ji Y; Gao DY; Cui XL; Liu DY; Yuan SY; Yuan MX;
    Diabetes Res Clin Pract; 2018 Oct; 144():236-244. PubMed ID: 30218743
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
    Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.